

Short Name	Full Title + Study Description	Type	Investigator	Contact
aSPIKE 2020-269	<b>A Master Protocol Aesessing the Safety, Tolerability, and Efficacy of <u>anti-SPIKE (S)</u> SARS-COV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19</b>	Treatment	<a href="#">Simeunovic,</a> <a href="#">Gordana</a>	Heather Benningfield <a href="mailto:Heather.Benningfield@spectrumhealth.org">Heather.Benningfield@spectrumhealth.org</a> 616.486.2042

*The purpose of this adaptive, phase 1/2/3, randomized, double-blinded, placebo-controlled master protocol is to evaluate the virologic efficacy REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2; and to evaluate the clinical efficacy of REGN10933 + REGN10987 compared to placebo in improving clinical status.*

[For More Information Click Here](#)

---